Overview

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate